AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

LTR PHARMA LTD

0.350

-0.030-7.89%

Volume:304.25K

Turnover:110.72K

Market Cap:63.34M

PE:-7.50

High:0.385

Open:0.380

Low:0.350

Close:0.380

Loading ...

Overview Company News Filings

Notification regarding unquoted securities - LTP-LTP.AX

ASX ALERT-LTP Completes Extractables Study Milestone for SPONTAN-LTP.AX

LTR Pharma Makes SPONTAN Product Available Through Pharmacy Network, Shares Jump 38%

MT Newswires Live

ASX Biggest Gainers

MT Newswires Live

BRIEF-LTR Pharma Signs Collaborative Agreement To Develop OMD Nasal Spray

LTR Pharma Signs Partnership on Intranasal Spray Development for Esophageal Motility Disorders

MT Newswires Live

BUZZ-Australia's LTR Pharma rises on new drug partnership deal

LTR Pharma Ltd - Agreement With Strategic Drug Solutions, Inc

THOMSON REUTERS

LTR Pharma Ltd - Ltr Signs Collaborative Agreement to Develop Omd Nasal Spray

THOMSON REUTERS

LTR Pharma Completes Pre-Investigational New Drug Meeting with US FDA

MT Newswires Live

LTR Pharma dips -6% as US growth plans confuse with two identical products to be launched

The Market Herald

BRIEF-Ltr Pharma Says FDA Provides Path To Approval For Spontan

LTR Pharma Ltd - FDA Provides Path to Approval for Spontan

THOMSON REUTERS

Here's Why We're Not Too Worried About LTR Pharma's (ASX:LTP) Cash Burn Situation

Simply Wall St.

LTR Pharma Joins Forces with Pharmaceutical Wholesaler for Erectile Dysfunction Treatment Distribution; Shares Up 12%

MT Newswires Live

BRIEF-LTR Pharma Signs National Pharmacy Distribution Agreement With Symbion

BUZZ-Australia's LTR Pharma rises on distribution deal for its erectile dysfunction product

LTR Pharma - Signs National Pharmacy Distribution Agreement With Symbion

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LTP.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LTP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTP.AU\",,,,,undefined,":{"symbol":"LTP.AU","market":"AU","secType":"STK","nameCN":"LTR PHARMA LTD","latestPrice":0.35,"timestamp":1753063652584,"preClose":0.38,"halted":0,"volume":304252,"delay":0,"nameEN":"LTR PHARMA LTD","floatShares":97895250,"shares":180977728,"eps":-0.046646,"marketStatus":"Trading","change":-0.03,"latestTime":"07-21 12:09:15 AEST","open":0.38,"high":0.385,"low":0.35,"amount":110720,"amplitude":0.092105,"askPrice":0.36,"askSize":2954,"bidPrice":0.35,"bidSize":29100,"shortable":3,"etf":0,"ttmEps":-0.046646,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1753077600000},"marketStatusCode":2,"adr":0,"listingDate":1702126800000,"exchange":"ASX","adjPreClose":0.38,"openAndCloseTimeList":[[1753056000000,1753077600000]],"volumeRatio":1.855538,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTP.AU\",,,,,undefined,":{"symbol":"LTP.AU","floatShares":97895250,"roa":"-20.56%","roe":"-33.62%","lyrEps":-0.0499,"volumeRatio":1.855538,"shares":180977728,"dividePrice":0,"high":0.385,"amplitude":0.092105,"preClose":0.38,"low":0.35,"week52Low":0.27,"pbRate":"1.85","psRate":"126.76","week52High":2.15,"institutionHeld":0,"latestPrice":0.35,"committee":0.815686,"eps":-0.046646,"divideRate":0,"volume":304252,"delay":0,"ttmEps":-0.046646,"open":0.38,"prevYearClose":0.81,"prevWeekClose":0.38,"prevMonthClose":0.29,"prevQuarterClose":0.29,"fiveDayClose":0.29,"twentyDayClose":0.285,"sixtyDayClose":0.375},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LTP.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551792514","title":"Notification regarding unquoted securities - LTP-LTP.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2551792514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551792514?lang=en_us&edition=fundamental","pubTime":"2025-07-14 06:40","pubTimestamp":1752446454,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250713:nASX4jGwSC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250713:nASX2cH9PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2547382000","title":"ASX ALERT-LTP Completes Extractables Study Milestone for SPONTAN-LTP.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547382000","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547382000?lang=en_us&edition=fundamental","pubTime":"2025-06-30 06:32","pubTimestamp":1751236352,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250629:nASX7k0QwD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250629:nASX7TlWFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2536662994","title":"LTR Pharma Makes SPONTAN Product Available Through Pharmacy Network, Shares Jump 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536662994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536662994?lang=en_us&edition=fundamental","pubTime":"2025-05-20 13:58","pubTimestamp":1747720685,"startTime":"0","endTime":"0","summary":"LTR Pharma  said its SPONTAN nasal spray product will be available through TerryWhite Chemmart's pharmacy network in Australia under its earlier distribution agreement with Symbion, according to a Tuesday Australian bourse filing.TerryWhite Chemmart is a subsidiary of EBOS Group  alongside Symbion, the filing said.LTR Pharma developed new commercial packaging for the SPONTAN intranasal spray, designed for pharmacy distribution and incorporating Therapeutic Goods Administration-compliant labeling, patient information materials, and pharmacy-standard barcodes.The expanded pharmacy rollout will allow the firm to gather real-world data on SPONTAN usage to support its regulatory strategy and preparations for a full commercial launch following regulatory approval in Australia.Its shares jumped over 38% in recent trading on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EBO.AU","XJO.AU","BK7103","XKO.AU","LTP.AU","BK7096","XAO.AU"],"gpt_icon":0},{"id":"2536645650","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2536645650","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536645650?lang=en_us&edition=fundamental","pubTime":"2025-05-20 10:12","pubTimestamp":1747707139,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Tuesday.ZOONO Group : +62%, AU$0.063Midas Minerals : +43%, AU$0.225LTR Pharma : +29%, AU$0.36Dateline Resources : +27%, AU$0.047Kingston Resources : +20%, AU$0.11Thunderbird Resources : +17%, AU$0.014Synertec Corporation : +16.00%, AU$0.029Southern Palladium : +15%, AU$0.225Lykos Metals : +14%, AU$0.016Finder Energy Holdings : +14%, AU$0.049","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPD.AU","KSN.AU","BK7050","BK7095","SOP.AU","THB.AU","ZNO.AU","LYK.AU","BK7116","BK7142","BK7501","FDR.AU","BK7104","MM1.AU","DTR.AU","BK7096","BK7036","LTP.AU"],"gpt_icon":0},{"id":"2533913142","title":"BRIEF-LTR Pharma Signs Collaborative Agreement To Develop OMD Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2533913142","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533913142?lang=en_us&edition=fundamental","pubTime":"2025-05-08 09:23","pubTimestamp":1746667392,"startTime":"0","endTime":"0","summary":"BRIEF-LTR Pharma Signs Collaborative Agreement To Develop OMD Nasal SprayMay 8 (Reuters) - LTR Pharma Ltd LTP.AX:LTR SIGNS COLLABORATIVE AGREEMENT TO DEVELOP OMD NASAL SPRAYAGREEMENT WITH STRATEGIC DRUG SOLUTIONS, INCFurther company coverage: LTP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RF37F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2533615918","title":"LTR Pharma Signs Partnership on Intranasal Spray Development for Esophageal Motility Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2533615918","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533615918?lang=en_us&edition=fundamental","pubTime":"2025-05-08 09:09","pubTimestamp":1746666596,"startTime":"0","endTime":"0","summary":"LTR Pharma  agreed to collaborate with Strategic Drug Solutions to co-develop Oroflow, a novel intranasal spray targeting esophageal motility disorders, according to a Thursday filing with the Australian bourse.Esophageal motility disorders are conditions that disrupt the normal movement of food and liquids down the esophagus, leading to swallowing difficulties and impacting quality of life, the filing said.The program is set to begin proof-of-concept testing in the coming months, according to the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2533499037","title":"BUZZ-Australia's LTR Pharma rises on new drug partnership deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2533499037","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533499037?lang=en_us&edition=fundamental","pubTime":"2025-05-08 08:52","pubTimestamp":1746665572,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's LTR Pharma rises on new drug partnership deal** Shares of Australia's LTR Pharma LTP.AX rise as much as 10.4% to A$0.425, their highest levels since May 2** The biopharmaceutical firm signs a collaborative agreement with Strategic Drug Solutions ** The agreement is to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders - a group of conditions that cause impaired swallowing ** Stock has fallen 52.5% so far this year  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL6N3RG011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2533995563","title":"LTR Pharma Ltd - Agreement With Strategic Drug Solutions, Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2533995563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533995563?lang=en_us&edition=fundamental","pubTime":"2025-05-08 06:35","pubTimestamp":1746657347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF37F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2533955509","title":"LTR Pharma Ltd -  Ltr Signs Collaborative Agreement to Develop Omd Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2533955509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533955509?lang=en_us&edition=fundamental","pubTime":"2025-05-08 06:35","pubTimestamp":1746657347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF37F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2522892089","title":"LTR Pharma Completes Pre-Investigational New Drug Meeting with US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2522892089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522892089?lang=en_us&edition=fundamental","pubTime":"2025-03-26 14:26","pubTimestamp":1742970370,"startTime":"0","endTime":"0","summary":"LTR Pharma  said it completed a successful pre-investigational new drug meeting with the US Food and Drug Administration, providing a defined path to approval for its SPONTAN intranasal spray, according to a Wednesday Australian bourse filing.The meeting resulted in an alignment on a streamlined clinical development path, including one pivotal safety and efficacy trial and a multi-dose pharmacokinetic study.The FDA broadly endorsed LTR's non-clinical toxicology and chemistry, manufacturing and controls development plans. It plans to investigate the ability to use additional clinical trial data for the US with other regulatory submissions in key global markets.It also plans to introduce its vardenafil-based nasal spray Roxus into the US market. Roxus is being developed together with an Australian pharmaceutical partner in Australia and testing is being conducted to establish stability and shelf-life.Its shares fell 9% as of market close on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","XJO.AU","LTP.AU","BK7096"],"gpt_icon":0},{"id":"2522898712","title":"LTR Pharma dips -6% as US growth plans confuse with two identical products to be launched","url":"https://stock-news.laohu8.com/highlight/detail?id=2522898712","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522898712?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:54","pubTimestamp":1742957640,"startTime":"0","endTime":"0","summary":"LTR Pharma  has unveiled its latest grand plan to further expand into the U.S. market – with a product called Roxus it says taps into “personalised healthcare.”Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.But markets haven’t liked the news: Shares were down -6.3% heading in early afternoon trades on Wednesday. That could be because of confusion around what Roxus is, as opposed to LTR Pharma’s flagship drug SPONTAN, and whether or not Roxus will require years of clinical trials.“LTR Pharma is advancing a dual-track US market strategy with the introduction of our new product, Roxus, a vardenafil-based nasal spray targeting the growing personalised healthcare sector,” LTR wrote on Wednesday.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified fin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/ltr-pharma-dips-6-as-us-growth-plans-confuse-with-two-identical-products-to-be-launched-2025-03-26/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2522854505","title":"BRIEF-Ltr Pharma Says FDA Provides Path To Approval For Spontan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522854505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522854505?lang=en_us&edition=fundamental","pubTime":"2025-03-26 09:31","pubTimestamp":1742952699,"startTime":"0","endTime":"0","summary":"BRIEF-Ltr Pharma Says FDA Provides Path To Approval For SpontanMarch 26 (Reuters) - LTR Pharma Ltd LTP.AX:FDA PROVIDES PATH TO APPROVAL FOR SPONTANFurther company coverage: LTP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q81IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2522839353","title":"LTR Pharma Ltd - FDA Provides Path to Approval for Spontan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522839353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522839353?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:59","pubTimestamp":1742939987,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2516583297","title":"Here's Why We're Not Too Worried About LTR Pharma's (ASX:LTP) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2516583297","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516583297?lang=en_us&edition=fundamental","pubTime":"2025-03-01 07:19","pubTimestamp":1740784772,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. Indeed, LTR Pharma  stock is up 107% in the last year, providing strong gains for shareholders. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So notwithstanding the buoyant share price, we think it's well worth asking whether LTR Pharma's cash burn is too risky. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.When Might LTR Pharma Run Out Of Money?How Is LTR Pharma's Cash Burn Changing Over Time?Since it has a market capitalisation of AU$109m, LTR Pharma's AU$5.3m in cash burn equates to about 4.9% of its market value. That's a low proportion, so","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-too-231932087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2505080852","title":"LTR Pharma Joins Forces with Pharmaceutical Wholesaler for Erectile Dysfunction Treatment Distribution; Shares Up 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505080852","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505080852?lang=en_us&edition=fundamental","pubTime":"2025-01-23 09:55","pubTimestamp":1737597326,"startTime":"0","endTime":"0","summary":"LTR Pharma  partnered with pharmaceutical wholesaler Symbion to establish national distribution capabilities for Spontan, a nasal spray treatment for erectile dysfunction, according to a Wednesday filing with the Australian bourse.Symbion will offer warehousing, inventory management, and nationwide distribution services for Spontan starting in March, the filing said.The operational integration is scheduled for rollout in the second quarter, per the filing.Shares were up 12% in midday trade Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2505753623","title":"BRIEF-LTR Pharma Signs National Pharmacy Distribution Agreement With Symbion","url":"https://stock-news.laohu8.com/highlight/detail?id=2505753623","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505753623?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:31","pubTimestamp":1737509460,"startTime":"0","endTime":"0","summary":"BRIEF-LTR Pharma Signs National Pharmacy Distribution Agreement With SymbionJan 22  - LTR Pharma Ltd LTP.AX:SIGNS NATIONAL PHARMACY DISTRIBUTION AGREEMENT WITH SYMBIONAGREEMENT ENABLES NATIONWIDE DISTRIBUTION OF SPONTAN VIA SYMBION'S EXTENSIVE NETWORKFurther company coverage: LTP.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH20B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2505758441","title":"BUZZ-Australia's LTR Pharma rises on distribution deal for its erectile dysfunction product","url":"https://stock-news.laohu8.com/highlight/detail?id=2505758441","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505758441?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:22","pubTimestamp":1737508953,"startTime":"0","endTime":"0","summary":"** Shares of LTR Pharma    rise 7.9% to A$0.755   ** The biopharmaceutical firm rose as much as 17.9% earlier in the day, their biggest intraday gain since early November   ** Co enters an agreement with Australian pharmaceutical wholesaler Symbion for nation-wide distribution for SPONTAN   ** SPONTAN is LTR Pharma's lead product for treatment of erectile dysfunction   ** About 1.2 mln shares change hands, compared with 30-day average trading volume of 669,941 shares    ** Stock down 13.6% YTD, as of last close  ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XAO.AU","XJO.AU","BK7096","XKO.AU","LTP.AU"],"gpt_icon":0},{"id":"2505871587","title":"LTR Pharma - Signs National Pharmacy Distribution Agreement With Symbion","url":"https://stock-news.laohu8.com/highlight/detail?id=2505871587","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505871587?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:40","pubTimestamp":1737495631,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH20B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTP.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LTP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LTP.AU\",market:\"AU\",,,undefined,":[]}}